Operating Income for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's current operating income (TTM) is $3.58B USD. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingOperating IncomeSwitch metric
TTM (last 4 quarters)
$3.58B
YoY change
-10.3%
5Y CAGR
+0.0%
Peak year (2021)
$8.95B
Cumulative operating income
$39.95B
Operating Income history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Operating Income history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Operating Income | YoY |
|---|---|---|---|---|
| 2025 | $3.58B | -10.3% | ||
| 2024 | $3.99B | -8.2% | ||
| 2023 | $4.35B | -19.3% | ||
| 2022 | $5.39B | -39.8% | ||
| 2021 | $8.95B | +150.1% | ||
| 2020 | $3.58B | +61.9% | ||
| 2019 | $2.21B | -12.8% | ||
| 2018 | $2.53B | +21.9% | ||
| 2017 | $2.08B | +56.3% | ||
| 2016 | $1.33B | +6.3% | ||
| 2015 | $1.25B | +51.9% | ||
| 2014 | $823.92M | +10.9% | ||
| 2013 | $743.05M | +61.4% | ||
| 2012 | $460.51M | -324.5% | ||
| 2011 | -$205.16M | +110.5% | ||
| 2010 | -$97.47M | +31.5% | ||
| 2009 | -$74.10M | -17.5% | ||
| 2008 | -$89.83M | -21.5% | ||
| 2007 | -$114.45M | +6.7% | ||
| 2006 | -$107.31M | -13.8% | ||
| 2005 | -$124.42M | -2303.7% | ||
| 2004 | $5.65M | -105.6% | ||
| 2003 | -$99.99M | -18.0% | ||
| 2002 | -$121.95M | +42.3% | ||
| 2001 | -$85.68M | +239.0% | ||
| 2000 | -$25.28M | +6.2% | ||
| 1999 | -$23.80M | +90.4% | ||
| 1998 | -$12.50M | +66.7% | ||
| 1997 | -$7.50M | -56.6% | ||
| 1996 | -$17.30M | +127.6% | ||
| 1995 | -$7.60M | -74.0% | ||
| 1994 | -$29.20M | -24.7% | ||
| 1993 | -$38.80M | +112.0% | ||
| 1992 | -$18.30M | +90.6% | ||
| 1991 | -$9.60M | +190.9% | ||
| 1990 | -$3.30M | — |
Operating Income values are taken from Regeneron Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual operating income for Regeneron Pharmaceuticals (REGN) came in at $3.58B – declined 10.3% year-over-year.
Regeneron Pharmaceuticals operating income has recorded the values shown across consecutive periods, with a +0.0% compound annual growth rate over 2020–2025 (5 years).
Regeneron Pharmaceuticals operating income peaked at $8.95B in 2021; the latest annual figure is $3.58B in 2025 (60.0% below peak).
2021 marks the peak operating income at $8.95B, with the historical low of -$205.16M recorded in 2011.
Among 8 Healthcare peers, Regeneron Pharmaceuticals (REGN) ranks 9th; the peer median for operating income is $22.84B.
Regeneron Pharmaceuticals Operating Income by Year
Regeneron Pharmaceuticals Operating Income 2025: $3.58B
Regeneron Pharmaceuticals operating income in 2025 was $3.58B, declined 10.3% below 2024.
Regeneron Pharmaceuticals Operating Income 2024: $3.99B
Regeneron Pharmaceuticals operating income in 2024 was $3.99B, declined 8.2% below 2023.
Regeneron Pharmaceuticals Operating Income 2023: $4.35B
Regeneron Pharmaceuticals operating income in 2023 was $4.35B, declined 19.3% below 2022.
Regeneron Pharmaceuticals Operating Income 2022: $5.39B
Regeneron Pharmaceuticals operating income in 2022 was $5.39B, plunged 39.8% below 2021.
Regeneron Pharmaceuticals Operating Income 2021: $8.95B
Regeneron Pharmaceuticals operating income in 2021 was $8.95B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Operating Income
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest operating income.
| Company | Operating Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $127.66B | Healthcare |
| Eli Lilly and Company (LLY) | $29.70B | Healthcare |
| Merck & Co., Inc. (MRK) | $26.78B | Healthcare |
| Johnson & Johnson (JNJ) | $25.60B | Healthcare |
| AbbVie Inc. (ABBV) | $20.09B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $18.96B | Healthcare |
| AstraZeneca PLC (AZN) | $13.74B | Healthcare |
| Amgen Inc. (AMGN) | $10.68B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's operating income?
- Latest reported operating income for Regeneron Pharmaceuticals (REGN) is $3.58B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals operating income changed year-over-year?
- Regeneron Pharmaceuticals (REGN) operating income changed -10.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals operating income?
- Regeneron Pharmaceuticals (REGN) operating income compound annual growth rate is +0.0% over the most recent 5 years available.
When did Regeneron Pharmaceuticals operating income hit its highest annual value?
- Regeneron Pharmaceuticals operating income reached its highest annual value of $8.95B in 2021.
What was Regeneron Pharmaceuticals operating income in 2024?
- Regeneron Pharmaceuticals (REGN) operating income in 2024 was $3.99B.
What was Regeneron Pharmaceuticals operating income in 2025?
- Regeneron Pharmaceuticals (REGN) operating income in 2025 was $3.58B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.